Fecal transplant to help liver cancer respond to standard drugs
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies whether a fecal microbiota transfer (a “gut bacteria transfer” from a donor) can help liver cancer patients overcome resistance to atezolizumab and bevacizumab. It aims to improve how well the standard medicines control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- You have confirmed liver cancer (HCC) by scan or biopsy
- Your liver cancer can’t be removed by surgery, transplant, or local procedures
- Your liver function tests are fairly good (Child-Pugh A or B) and your health is strong enough (ECOG 0–1)
- You have measurable cancer on scans (meets RECIST criteria)
- You are eligible to receive atezolizumab plus bevacizumab as standard care
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether transplanting healthy stool bacteria into your gut can help your own immune system fight liver cancer that has stopped responding to the standard first combination treatment (atezolizumab + bevacizumab). It is for patients whose liver cancer has started growing quickly despite that treatment.
This trial tests combining a fecal transplant (healthy donor bacteria) with two drugs—QL1706 (an immunotherapy) and bevacizumab (a blood vessel blocker)—for people with advanced liver cancer that hasn't been treated before. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests whether giving a fecal transplant (a procedure that replaces the bacteria in your gut) can help people with advanced liver cancer whose current treatment has stopped working. It may help boost your immune system to fight the cancer.
This trial tests whether transplanting healthy gut bacteria (fecal microbiota transplantation) can help your liver cancer become sensitive again to treatment that has stopped working. It may help reverse drug resistance and improve outcomes for people with advanced liver cancer.
This trial studies how the gut (your digestive system) affects how well immunotherapy works for advanced liver cancer. You'll have a colonoscopy (a test to look inside your bowel) and provide samples, which could help doctors improve treatment for you and others.
This trial studies whether transferring healthy gut bacteria (from a donor sample) can improve outcomes for people with liver cirrhosis who have worsening complications. It may help by changing the gut microbiome, which can influence inflammation and liver health.
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.